For research use only. Not for therapeutic Use.
Elafibranor(CAT: I005500) is a potent dual agonist of the peroxisome proliferator-activated receptors alpha and delta (PPARα/δ), making it a key compound in the treatment of metabolic disorders. It has been widely studied for its potential to treat nonalcoholic steatohepatitis (NASH) and other liver diseases. By modulating lipid metabolism, inflammation, and insulin sensitivity, Elafibranor helps reduce liver fat accumulation and improves overall metabolic function. Its safety profile and efficacy have been investigated in clinical trials, positioning it as a promising therapeutic agent for metabolic and inflammatory diseases.
| Catalog Number | I005500 |
| CAS Number | 923978-27-2 |
| Synonyms | 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid |
| Molecular Formula | C22H24O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+ |
| InChIKey | AFLFKFHDSCQHOL-IZZDOVSWSA-N |
| SMILES | CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)C=CC(=O)C2=CC=C(C=C2)SC |
